Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Authors:
- Haridas B. RodeHRHaridas B. Rode
- Stefanie HeynckSHStefanie Heynck
- Martin PeiferMPMartin Peifer
- Florian FischerFFFlorian Fischer
- Sabine KlüterSKSabine Klüter
- Vijaykumar G. PawarVPVijaykumar G. Pawar
- Cecile ReuterCRCecile Reuter
- Johannes M. HeuckmannJHJohannes M. Heuckmann
- Jonathan WeissJWJonathan Weiss
- Lars RuddigkeitLRLars Ruddigkeit
- Matthias RabillerMRMatthias Rabiller
Open Access
- 31 January 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (3) , 868-874
Abstract
Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small molecules to improve progression-free survival of patients with EGFR-mutated lung cancers. Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clinical activity in patients with T790M-mutant tumors. In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors. A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines. Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase. Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis. Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR. Cancer Res; 70(3); 868–74Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung CancerClinical Cancer Research, 2008
- Structural insights into how irreversible inhibitors can overcome drug resistance in EGFRBioorganic & Medicinal Chemistry, 2008
- A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBritish Journal of Cancer, 2007
- HKI-272 in Non–Small Cell Lung CancerClinical Cancer Research, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004